CUMBERLAND PHARMACEUTICALS INC
AI Executive Summary
AI-powered analysis of 10-Q filing content
Cumberland Pharmaceuticals shows severe operational deterioration with Q1 2026 revenues declining 22% to $9.1M while swinging to a $3.3M loss from $1.3M profit in Q1 2025. The company maintains concerning liquidity with $5.2M revolving credit and accumulated deficit expanding to $30.1M, indicating persistent profitability challenges.
Red Flags Detected (8)
Revenue decline of 22% year-over-year ($11.7M to $9.1M)
Operating loss of $3.1M vs $1.3M profit in prior year
Net loss of $3.3M vs $1.3M profit in Q1 2025
5 more red flags detected
Key Takeaways
Fundamental business deterioration with revenue down and costs increasing
Operating leverage working against the company as fixed costs exceed declining revenues
2 more takeaways
Filing Overview
What This Means
High Risk Filing: This company is showing signs of financial stress or significant operational challenges.
Deteriorating Trend: Conditions are worsening compared to previous filings. This may create opportunities for service providers.
Quarterly Report: Interim filing with unaudited financial data for the quarter.